By Asmau Ahmad
The French-British pharmaceutical collaboration, Sanofi-GSK, announced on Friday that their COVID-19 vaccine has been successfully tested against the Omicron variant of the Coronavirus.
The effectiveness of the protein-based vaccine against Omicron is around 72 per cent regarding symptomatic infection, according to a phase 3 studies, Sanofi reported.
Meanwhile, for people already recovered, effectiveness goes up to 93 per cent, as 13,000 adults participated in the second stage of the phase 3 study.
The vaccine contains antigens for the COVID variants D614 and Beta.
Sanofi and GSK will submit the results of the study to the European Medicines Agency next week in order to support their application for the vaccine to be authorised.
The two companies are also researching a specially adapted booster that will also be based on a beta variant of the virus.
Sanofi did not make any predictions about when they expect their vaccine to gain authorisation.
